Literature DB >> 11020579

The rationale and technique of staged-volume arteriovenous malformation radiosurgery.

B E Pollock1, R W Kline, S L Stafford, R L Foote, P J Schomberg.   

Abstract

PURPOSE: Stereotactic radiosurgery is an effective management strategy for properly selected arteriovenous malformation (AVM) patients. However, the risk of postradiosurgical radiation-related injury generally limits this procedure to patients with AVMs of an average diameter of 3 cm or less. Radiosurgery of large AVMs in a planned staged fashion was undertaken to limit the radiation exposure to the surrounding normal brain. METHODS AND MATERIALS: Between April 1997 and December 1999, 10 patients with a median AVM volume of 17.4 cm(3) (range, 7.4-53.3 cm(3)) underwent staged-volume radiosurgery (23 procedures). At the first radiosurgical procedure, the total volume of the AVM is estimated and a dose plan calculated that covers 10 cm(3)-15 cm(3), or one-half the nidus volume if the AVM is critically located (brainstem, thalamus, or basal ganglia). At 6-month intervals thereafter, radiosurgery was repeated to different portions of the AVM with the previous dose plan(s) being re-created utilizing intracranial landmarks to minimize radiation overlap. Radiosurgical procedures were continued until the entire malformation has been irradiated.
RESULTS: The radiation dosimetry of staged-volume AVM radiosurgery was compared to hypothetical single-session procedures for the 10 patients. Staged-volume radiosurgery decreased the 12-Gy volume by an average of 11.1% (range, 4.9-21%) (p < 0.001). The non-AVM 12-Gy volume was reduced by an average of 27.2% (range, 12.5-51.3%) (p < 0.001). DISCUSSION: Staged-volume radiosurgery of large AVMs results in less radiation exposure to the adjacent brain. Further follow-up is needed to determine whether this technique provides a high rate of AVM obliteration while maintaining an acceptable rate of radiation-related complications.

Entities:  

Mesh:

Year:  2000        PMID: 11020579     DOI: 10.1016/s0360-3016(00)00696-9

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  8 in total

1.  Acute management of brain arteriovenous malformations.

Authors:  Andreas Hartmann; J P Mohr
Journal:  Curr Treat Options Neurol       Date:  2015-05       Impact factor: 3.598

2.  A technique for achieving submillimeter accuracy of volume-staged stereotactic radiosurgery.

Authors:  Lijun Ma; Shannon Fogh; Nalin Gupta; Andrew Hwang; Dilini Pinnaduwage; Jean Nakamura; Igor Barani; Michael McDermott; Penny K Sneed; David A Larson; Arjun Sahgal
Journal:  J Radiosurg SBRT       Date:  2012

3.  Endovascular therapy followed by stereotactic radiosurgery for cerebral arteriovenous malformations.

Authors:  Y Arai; Y Handa; H Ishii; Y Ueda; H Uno; T Nakajima; S Hirose; T Kubota
Journal:  Interv Neuroradiol       Date:  2006-06-15       Impact factor: 1.610

4.  Neurovascular radiosurgery.

Authors:  M Söderman; W Y Guo; B Karlsson; D M Pelz; E Ulfarsson; T Andersson
Journal:  Interv Neuroradiol       Date:  2006-12-13       Impact factor: 1.610

5.  Spatiotemporal Fractionation Schemes for Irradiating Large Cerebral Arteriovenous Malformations.

Authors:  Jan Unkelbach; Marc R Bussière; Paul H Chapman; Jay S Loeffler; Helen A Shih
Journal:  Int J Radiat Oncol Biol Phys       Date:  2016-02-06       Impact factor: 7.038

6.  Embolization and radiosurgery for arteriovenous malformations.

Authors:  Andres R Plasencia; Alejandro Santillan
Journal:  Surg Neurol Int       Date:  2012-04-26

7.  Time-Staged Gamma Knife Stereotactic Radiosurgery for Large Cerebral Arteriovenous Malformations: A Preliminary Report.

Authors:  Hye Ran Park; Jae Meen Lee; Jin Wook Kim; Jung-Ho Han; Hyun-Tai Chung; Moon Hee Han; Dong Gyu Kim; Sun Ha Paek
Journal:  PLoS One       Date:  2016-11-02       Impact factor: 3.240

Review 8.  Current concepts in stereotactic radiosurgery - a neurosurgical and radiooncological point of view.

Authors:  Jan Vesper; B Bölke; C Wille; P A Gerber; C Matuschek; M Peiper; H J Steiger; W Budach; G Lammering
Journal:  Eur J Med Res       Date:  2009-03-17       Impact factor: 2.175

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.